Tocotrienols and tocotrienol-like compounds and methods for their use
AssigneeLipogenics, Inc.
InventorsRonald H. Lane, Asaf A. Qureshi, Winston A. Salser
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel tocotrienols and tocotrienol-like compounds displaying biological activity. The tocotrienols and tocotrienol-like compounds of this invention may be conveniently obtained from biological sources or by chemical synthesis and may be used in pharmaceutical compositions, foodstuffs and dietary supplements. This invention also relates to the use of tocotrienols, tocotrienol-like compounds, and mixtures thereof, as hypocholesterolemic, antithrombotic, antioxidizing, antiatherogenic, antiinflammatory and immunoregulatory agents, or as agents useful to decrease lipoprotein (a) concentration in the blood or to increase feed conversion efficiency.
Claims39
A tocotrienol comprising 3,4-dihydro-2-(4,8,12-trimethyltrideca-3'(E), 7'(E), 11'-trienyl)-2H-1-benzopyran-6-ol), and having the structure:
- ##STR10##
A tocotrienol comprising:
- ##STR11##
A composition comprising a tocotrienol compound resulting from a process comprising the steps of:
- stabilizing a biological material by heating;
- extracting the biological material with a solvent to obtain an oil;
- eluting the oil from an HPLC colunto under the following conditions:
- 20 .mu.l sample, .mu.-Porasil column (Waters column, 10.mu., 4 mm.times.30 cm) using an isocratic system of hexane and isopropanol (99.75% :0.25%, v/v) at a flow rate of 1.3 ml/min.;
- and
- collecting compounds having an HPLC elution time of greater than 22 minutes, said compounds being detectable at an excitation wave length of about 295 nm, and having an emission wave length of about 330 nm, UV absorption at about 295 nm, and an ability to inhibit the synthesis .beta.-hydroxy-.beta.-methyl glutaryl coenzyme A reductase.
Dependencies are inferred from the claim text.